Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriFiloVax
- Development stage
- Preclinical
- Lead developer
- Soligenix
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TriFiloVax is a trivalent filovirus vaccine candidate developed by Soligenix in collaboration with the University of HawaiʻI at Mānoa. It is designed to provide protection against three major filoviruses: Ebola virus (Zaire ebolavirus), Sudan virus (Sudan ebolavirus), and Marburg virus (Marburg marburgvirus). The vaccine utilizes a shared glycoprotein platform where recombinant protein subunits (glycoproteins) are produced using a proprietary insect cell expression system. It is formulated with the CoVaccine HT™ adjuvant, a nanoemulsion licensed from BTG Specialty Pharmaceuticals (a division of Boston Scientific) that is designed to enhance both humoral and cellular immune responses. A key feature of the TriFiloVax platform is its potential for heat stability, which would facilitate distribution in regions with limited cold-chain infrastructure. The program has received support from the National Institutes of Health (NIH) and is intended for both pre-exposure prophylaxis and potential use in outbreak settings.
- Brand names
- TriFiloVax
- Other names
- trivalent filovirus vaccineSoligenix filovirus vaccineEbVax + SuVax + MarVax
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on TriFiloVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriFiloVax.